A carregar...
Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
BACKGROUND: Real-world data regarding outcomes of idiopathic pulmonary fibrosis (IPF) are scarce, outside of registries. In France, pirfenidone and nintedanib are only reimbursed for documented IPF, with similar reimbursement criteria with respect to disease characteristics, prescription through a d...
Na minha lista:
| Publicado no: | Respir Res |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8094468/ https://ncbi.nlm.nih.gov/pubmed/33947414 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-021-01714-y |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|